Introduction
Inflammatory bowel disease [IBD] results from an exaggerated T cell response to gut microbiota in genetically predisposed hosts. This response is not adequately counteracted by regulatory CD4+Foxp3+ T cells [Treg] , although increased. 1 We have recently described both in mice with experimental colitis 2 and in humans with ileal pouchanal anastomosis [IPAA] for ulcerative colitis [UC] 3 the occurrence of another type of regulatory T cell in the intestinal lamina propria. This cell is a CD4+ T cell that bears surface TGF-β linked to its latency associated peptide [LAP+ cells] but does not express Foxp3. These cells are increased, in mice, in the presence of increased intestinal permeability and during the homeostatic response to a transient increase of intestinal permeability. 4, 5 Their in vivo regulatory activity has been proven by the fact that they contribute to the prevention of 2,4,6-Trinitrobenzenesulfonic acid [TNBS] and adoptive transfer colitis in mice. 5, 6 Their contribution was found to be crucial for the protection from TNBS colitis, since transfer of CD4+LAP+ depleted cells enriched with CD4+ Foxp3+ cells were not able to prevent TNBS colitis in recipient mice. 5 Notable characteristics of these cells are that in mice they require IL-10 and TLR2 for their in vivo expansion 2, 5 and they express LAP independently of Foxp3 in the presence of TGF-β. 7 Initial description of their properties in humans showed that CD4+LAP+ peripheral T cells produce IL-10 and TGF-β and are expanded in vitro by polyclonal stimulation in the presence of IL-2 and IL-8. 8 In the present study, we investigated the frequency and function of lamina propria CD4+LAP+ in IBD. We found that they were selectively increased in endoscopically active UC patients, showing a significant increase of IL-17 expression when compared with controls. Functional studies demonstrated that LP CD3+CD8-[ CD4]LAP+CD25-cells isolated from UC patients showed reduced or no ability to inhibit autologous PB CD3+CD8-[CD4]LAP-CD25-cell proliferation when compared with controls. Depletion of CD3+CD8-[CD4] LAP+ IL-17+ cells increases the suppressor ability of CD4 LAP+ cells.
Materials and Methods

Patients and tissues
Surgical specimens
Surgical specimens were taken from macroscopically inflamed areas of 5 ilea and 5 colons of a total of 10 patients affected by Crohn's disease, and from colonic macroscopically inflamed areas of 11 patients affected by ulcerative colitis. Mucosal samples were also collected from macroscopically unaffected ileal or colonic areas [6 ileal specimens, 11 colonic specimens] of a total of 17 patients undergoing surgery for colonic cancer.
Biopsy specimens
Endoscopic mucosal biopsies were obtained from a total of 23 UC patients [13 males, 10 females, mean age: 48.8 ± 4.5 year] and from a total of 19 control subjects undergoing colonoscopy for colonic cancer screening and suspected functional bowel disorders in which histology confirmed the absence of inflammatory changes. Biopsies were taken from inflamed areas in UC patients with active disease, from previously inflamed areas in UC patients with endoscopic remission [anamnestic information] and in matched areas in control subjects. Diagnosis of Crohn's disease and ulcerative colitis was ascertained according to established criteria, and site and extent of the disease were confirmed by histology.
Patients
In UC patients, disease activity was assessed by endoscopic modified Baron Score [mBs] . 9 Accordingly, patients with an mBs >1 were considered as active patients [12 patients] and 11 patients were considered as in remission. At time of surgery/endoscopy none of the active patients was treated with cyclosporine, azathioprine, or anti-TNF antibodies. Two UC patients in remission were receivinging azathioprine. In UC patients, disease duration was 11 ± 2.5 years with no difference between active and inactive patients
Ethical considerations
All participants provided written informed consent. Ethical approval was provided by the Istituto Superiore di Sanità's Ethical Committee, reference: Pre-C-899/14.
Cells isolation
LPMC were isolated from freshly resected mucosa or biopsies using a previously described DDT-EDTA collagenase method. 3, 10 Briefly, strips of mucosa [6-8 g Since CD161+ cell population has been reported to be increased in UC 11, 12 and indirectly shown to contain sulfatide-reactive Type II NK-T cells, 12 in a subset of experiments we also evaluated CD161+ and CD161+ LAP+ cells. As previously reported, 11, 12 we observed a higher percentage of CD161+ cells in UC than in control samples in CD3+CD8-[CD4] LP cells; however, we observed very few, if any, CD161+LAP+ cells in controls or in active UC samples, suggesting that the great majority of LAP+ cells are not CD161+.
Cell populations' purification
In experiments involving cell-sorting, LPMC and PBMC were stained with anti-CD3, anti-CD8, anti-LAP [TGF-β1], and anti-CD25 abs and different T cell populations were sorted using a FACSAria Cell 
Statistical analysis
Data were analysed in the GraphPad Prism statistical PC program [GraphPad Software, San Diego, CA, USA] using the Mann-Whitney U test and Spearman correlation. A level of p < 0.05 was considered statistically significant. 
Results
Lamina propria CD4+LAP+ are increased in ulcerative colitis and not in Crohn's disease
We started our observations investigating the CD4+LAP+ cells frequency in LPMCs isolated from severely inflamed surgical specimens of patients with UC, Crohn's disease [CD], and controls. As shown in Figure 1 , frequencies of LP CD4+LAP+ cells were selectively increased above control values in LPMC isolated from surgical UC specimens and not in LPMC isolated from ileal or colonic surgical CD specimens.
LP CD4+LAP+ are increased in active UC and are predominantly Foxp3 negative
We then analysed the CD4+LAP+ cells frequencies in LPMCs from biopsy specimens from UC patients showing endoscopically active and inactive disease assessed with the modified Baron score. 9 As shown in Figure 2 [panels A and B], LPMC isolated from patients with active endoscopic disease showed a significant increase in the frequency of LP CD4+LAP+ as well as CD4+Foxp3+ cells when compared with LPMC isolated from inactive patients and controls. To establish the possible overlap between the two populations, we assessed the frequency of CD4+LAP+Foxp3+ cells. The percentage of cells expressing both markers was very low, with a significant increase in active UC patients when compared with patients with endoscopic remission and controls [ Figure 2, 
Depletion of LP CD4+LAP+ IL17+ cells increases the suppressor activity of LP CD4+LAP+ cells
Since proportion of IL-17 expression was significantly increased in LP CD4+LAP+ cells of UC patients, we investigated whether the reduced suppressive capacity of CD4+LAP+ cells isolated from patients with active disease was somehow linked to the expression of IL-17 in LAP+ cells. As shown in Figure 5 
Discussion
In the present study we demonstrated that in IBD LP CD4+LAP+ cells are significantly increased in UC and not in CD. These cells are mostly Foxp3-and co-express IL-17, IL-10, and IFN-γ both in control and in UC patients. Notably, in active UC patients LP CD4+LAP+ Foxp3-cells are enriched for IL-17 expression. When isolated from LP of non-inflammatory controls, CD4+LAP+ cells show suppressor activity which is greatly reduced in LP CD4+LAP+ cells isolated from UC patients. The reduced suppressor activity is linked to their IL-17 intracellular expression, since selective depletion of LP CD4+LAP+IL-17+ cells from the CD4+LAP+CD25-population increases the suppressor activity of the latter cell population. This finding does not exclude the possibility that additional factors, although to a lesser extent, might influence CD4+LAP+ cells suppressor activity in UC. Reasons for the selective increase of LP CD4+LAP+ cells in UC when compared with CD may reside in the different mucosal cytokine environment associated with the two diseases favouring or not the expansion of CD4+LAP+ cells. In mice, CD4+LAP+ cell expansion has been reported to be dependent on IL-10 and TGF-β. 2, 5, 15 In a previous study, we demonstrated that, in vitro, aCD3/2/28 stimulated LP T cells isolated from UC patients produced a significantly increased amount of TGF-β when compared with LP T cells isolated from CD patients that showed values comparable to controls. 10 Moreover, previous studies showed a highly significant increase of IL-10 mRNA levels and an increased frequency of IL-10-positive cells in LP T cells isolated from patients with UC when compared with LP T cells isolated from CD patients that showed values not different from controls. 14 Similarly, IL-10 serum levels were significantly increased in UC active patients when compared with CD patients and controls. 16 In the present study, confirming previous studies, 14 we observed an increased frequency of LP CD4+IL-10-positive cells in UC, suggesting that increased TGF-β and IL-10 production may have a role in the expansion of CD4+LAP+cells in ulcerative colitis.
The LP CD4+LAP+ cell population described in the present study is predominantly Foxp3-as previously described in human peripheral blood 8 and in tumour-infiltrating lymphocytes in colorectal cancer, 17 as well as in mice colonic lamina propria 2,4,5 and airway mucosa. 15 In animal models of experimental colitis 4, 5, 6 and asthmatic lung inflammation, 15 CD4+LAP+ Foxp3-cells have been proven to be regulatory cells. In human peripheral blood and in colonic cancerinfiltrating lymphocytes, they exhibit suppressive activity in vitro; 8, 17 therefore they represent a regulatory T cell subset different from Foxp3+ Treg cells also in humans.
In the present study, we observed a significant reduction of suppressive activity of LP CD4+LAP+CD25-cells isolated from inflamed UC specimens when compared with suppressor activity of LP CD4+LAP+CD25-cells isolated from control specimens, suggesting that the inflammatory milieu influences their suppressive ability. In particular, we demonstrated that in UC, inflammation is associated with a significant increase in percentage of IL-17+ cells in LP CD4+LAP+ population and that this subpopulation of CD4+LAP+ cells does not show in vitro suppressor ability. In patients with colorectal cancer, 17 it was shown that tumour-infiltrating CD4+LAP+ lymphocytes showed a high suppressor activity, and exhibited an increase in IL-10 and a reduction of IFN-γ and IL-17 intracellular expression when compared with CD4+LAP+ in tumour-free mucosa. These data suggest that CD4+LAP+ suppressor activity was mostly associated with intracellular IL-10 expression although, in the reported studies, the suppressor ability of CD4+LAP+ isolated from tumour-free mucosa was not assessed. In previous studies performed on human peripheral blood, 8 although CD4+LAP+ cells were characterised by their ability to secrete, upon activation, different cytokines [namely, IL-8, IL-9, IL-10, IFN-γ, and TGF-β], the contribution of CD4+LAP+ cell subsets expressing different cytokines to the suppression ability of the whole CD4+LAP+ cells population was not evaluated. To our knowledge, this is the first observation showing that CD4+LAP+ IL-17+ cells are not suppressor cells, since their removal increases the suppressive ability of CD4+LAP+ cells.
Whether CD4+LAP+IL-17+, CD4+LAP+IFN-γ+, and CD4+LAP+ IL-10+ cells represent distinct cell populations derived from an initial CD4+LAP+ cell that acquires, as a terminally differentiated cell, the ability to produce different cytokines under the influence of tissue microenvironment, is not known. It is also presently unknown whether CD4+LAP+ cells producing different cytokines can derive from an initial CD4+LAP+IL-10+ cell with regulatory function that changes its cytokine pattern and function under the influence of the local microenvironment. Similarly, it is not known whether CD4+LAP+ cells co-express multiple cytokines. Regardless of these aspects, it is interesting to note that the type of cytokine produced by CD4+LAP+ are all influenced by TGF-β itself, suggesting a possible autocrine mechanism of cytokine production regulation. 18, 19, 20 Further studies focused on CD4+ LAP+ cells biology are necessary to clarify these issues.
Although we did not investigate the possible co-expression of different cytokines in LAP+ cells, from our results it appears that, at least in UC, the expression of IL-17 in CD4LAP+ cells reduces the overall ability of CD4LAP+ cells to inhibit autologous cell proliferation independently of concomitant co-expression of other cytokines in the CD4LAP+IL-17+ cells. The reduced suppressor activity of CD4LAP+ regulatory cells in UC reinforces the differences observed in the regulatory cell subsets between UC and CD, where a distinct population of Foxp3+ IL-17-producing CD4 T cells maintaining Treg-typical suppressor activity in vitro has been described in CD, but not in UC patients or healthy controls. 21 The above reported differences between CD and UC patients raise the possibility that the increased IL-17 production observed both in CD and UC may have different pathogenic relevance in the two diseases, being more relevant for the genesis and perpetuation of inflammation in UC as opposed to CD. This hypothesis is supported by recent studies that showed a significantly increased percentage of circulating Th17 cells in patients with active UC when compared with patients with CD 22 and the ability of serum IL-17A levels to reflect clinical disease severity and predict the course of disease in patients with ulcerative colitis. 23 Therefore, in CD, the reported failure of anti-IL-17 antibody administration to ameliorate the disease 24 might have been associated, at least in part, with a protective role of IL-17+/Foxp3+ T cell populations. The above reported differences between CD and UC patients highlight possible different outcomes in the two diseases of therapeutic strategies aimed to specifically block Th17 polarisation and function. 
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